The loss of blood flow autoregulation caused by diabetes is the result of the disruption of the TRPV2 protein. Even in the absence of diabetes, disrupted blood flow autoregulation causes damage closely resembling that seen in diabetic retinopathy.
Determining the structure of vitronectin, a protein implicated in age-related macular degeneration and some neurodegenerative disorders, and using pressure to alter the protein shape may help in the development of new treatments for AMD.
A new study reports that a new gene therapy shows promise in treating dry age-related macular degeneration. The gene therapy, ophNdi1, directly targets mitochondrial function that is malfunctioning in AMD.
The discovery of new genetic signatures associated with age-related macular degeneration may lead to better diagnosis and treatment of the currently incurable vision disorder.
Researchers say Black patients are at greater risk of advanced vision loss than white patients following a diagnosis of primary open angle glaucoma.
The way in which a patient is informed they have a specific eye disease can impact their psychological health and ability to deal with their condition in the long term.
Age-related changes in the retina may be driven by the loss of the pigment epithelium-derived factor protein. The findings could pave the way for the development of treatment for age-related macular degeneration and other age-related vision loss disorders.
The visual system adapts to the loss of photoreception by increasing sensitivity but simultaneously becomes deleteriously hyperactive. The findings could lead to new therapies to protect vision or reverse vision loss.
Researchers have identified a new genetic eye disease that affects the macula.
The AREDS2 dietary supplement that substitutes antioxidants lutein and zeaxanthin for beta-carotene reduces the risk of age-related macular degeneration progression, a new study reveals.
Cognitive tests that rely on vision-dependent tasks may skew results for up to 25% of adults over 50 with undiagnosed visual problems such as AMD and cataracts. This may lead to a misdiagnosis of mild cognitive impairment in older adults.
By the time most of us hit our 40s, our close-up vision starts to decline and we develop presbyopia. A new eye drop called Vuity claims to alleviate the symptoms of presbyopia, allowing people to gain clearer vision without the need for glasses or surgery. Researchers examine the potential benefits of using Vuity for people with presbyopia.
